

# Paola Rogliani

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1341783/paola-rogliani-publications-by-year.pdf>

**Version:** 2023-12-04

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

341  
papers

6,130  
citations

38  
h-index

63  
g-index

371  
ext. papers

7,552  
ext. citations

4.6  
avg, IF

6.42  
L-index

#	Paper	IF	Citations
341	Beyond Dual Bronchodilation - Triple Therapy, When and Why.. <i>International Journal of COPD</i> , <b>2022</b> , 17, 165-180	3	2
340	First Case of a COVID-19 Patient Infected by Delta AY.4 with a Rare Deletion Leading to a N Gene Target Failure by a Specific Real Time PCR Assay: Novel Omicron VOC Might Be Doing Similar Scenario?. <i>Microorganisms</i> , <b>2022</b> , 10,	4.9	2
339	Clinical Interpretation of Efficacy Outcomes in Pharmacological Studies on Triple Fixed-Dose Combination Therapy for Uncontrolled Asthma: Assessment of IRIDIUM and ARGON Studies.. <i>Journal of Experimental Pharmacology</i> , <b>2022</b> , 14, 1-5	3	1
338	The future of inhalation therapy in chronic obstructive pulmonary disease.. <i>Current Research in Pharmacology and Drug Discovery</i> , <b>2022</b> , 3, 100092	3	1
337	Inflammatory and contractile profile in LPS-challenged equine isolated bronchi: Evidence for IL-6 as a potential target against AHR in equine asthma.. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2022</b> , 102, 102125	3.5	1
336	Potential Drawbacks of ICS/LABA/LAMA Triple Fixed-Dose Combination Therapy in the Treatment of Asthma: A Quantitative Synthesis of Safety Profile.. <i>Journal of Asthma and Allergy</i> , <b>2022</b> , 15, 565-577	3.1	1
335	Stem Cell-Based Regenerative Therapy and Derived Products in COPD: A Systematic Review and Meta-Analysis. <i>Cells</i> , <b>2022</b> , 11, 1797	7.9	1
334	Use of face masks and allergic rhinitis from ragweed: why mention only total pollen count and not air pollution levels?. <i>International Forum of Allergy and Rhinology</i> , <b>2021</b> ,	6.3	
333	Rationale and Clinical Use of Bronchodilators in Adults with Bronchiectasis. <i>Drugs</i> , <b>2021</b> , 1	12.1	1
332	Acute effect of oxygen therapy on exercise tolerance and dyspnea perception in ILD patients. <i>Monaldi Archives for Chest Disease</i> , <b>2021</b> ,	2.7	1
331	Impact of long-acting muscarinic antagonists on small airways in asthma and COPD: A systematic review. <i>Respiratory Medicine</i> , <b>2021</b> , 189, 106639	4.6	0
330	Reply to Han et al.: impact on mortality of triple ICS/LABA/LAMA therapy in a population of COPD patients including also subjects with asthma-like profile. <i>Expert Review of Respiratory Medicine</i> , <b>2021</b> , 15, 579-581	3.8	4
329	New Avenues for Phosphodiesterase Inhibitors in Asthma. <i>Journal of Experimental Pharmacology</i> , <b>2021</b> , 13, 291-302	3	4
328	Sex differences in COPD management. <i>Expert Review of Clinical Pharmacology</i> , <b>2021</b> , 14, 323-332	3.8	3
327	SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines. <i>Vaccines</i> , <b>2021</b> , 9,	5.3	21
326	Response to letter to the editor. Again on IMPACT: exacerbation after abrupt discontinuation of ICS and pneumonia in fluticasone furoate-containing FDCs. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 943-945	4	
325	Factors Influencing the Efficacy of COVID-19 Vaccines: A Quantitative Synthesis of Phase III Trials. <i>Vaccines</i> , <b>2021</b> , 9,	5.3	17

324	Mortality in ETHOS: A Question of "Power". <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 203, 926-927	10.2	2
323	Quasibar minimalist lung volume reduction surgery. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2021</b> , 60, 598-606	3	2
322	Lessons from peculiar cases of anaphylaxis: why allergists should be prepared for the unexpected. <i>European Annals of Allergy and Clinical Immunology</i> , <b>2021</b> ,	1.3	2
321	Dexamethasone in Patients Hospitalized with COVID-19: Whether, When and to Whom. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	10
320	Management of COPD patients during COVID: difficulties and experiences. <i>Expert Review of Respiratory Medicine</i> , <b>2021</b> , 15, 1025-1033	3.8	0
319	Step-up and step-down approaches in the treatment of asthma. <i>Expert Review of Respiratory Medicine</i> , <b>2021</b> , 15, 1159-1168	3.8	2
318	Assessment of self-reported and objective daytime sleepiness in adult-onset myotonic dystrophy type 1. <i>Journal of Clinical Sleep Medicine</i> , <b>2021</b> , 17, 2383-2391	3.1	1
317	Medium-dose ICS-containing FDCs reduce all-cause mortality in COPD patients: an in-depth analysis of dual and triple therapies. <i>Expert Review of Respiratory Medicine</i> , <b>2021</b> , 1-9	3.8	0
316	Atherogenic Dyslipidemia on Admission Is Associated With Poorer Outcome in People With and Without Diabetes Hospitalized for COVID-19. <i>Diabetes Care</i> , <b>2021</b> , 44, 2149-2157	14.6	5
315	Radiological pitfalls associated with the diagnosis of usual interstitial pneumonia pattern on high-resolution computed tomography and associated findings: experience from a single Italian center. <i>Acta Radiologica</i> , <b>2021</b> , 62, 619-627	2	1
314	Depressive and anxiety symptoms in patients with SARS-CoV2 infection. <i>Journal of Affective Disorders</i> , <b>2021</b> , 278, 339-340	6.6	4
313	Advances in understanding of mechanisms related to increased cardiovascular risk in COPD. <i>Expert Review of Respiratory Medicine</i> , <b>2021</b> , 15, 59-70	3.8	2
312	Reduced risk of COVID-19 hospitalization in asthmatic and COPD patients: a benefit of inhaled corticosteroids?. <i>Expert Review of Respiratory Medicine</i> , <b>2021</b> , 15, 561-568	3.8	18
311	Guidance on nebulization during the current COVID-19 pandemic. <i>Respiratory Medicine</i> , <b>2021</b> , 176, 1062366	4.6	19
310	Prospects for severe asthma treatment. <i>Current Opinion in Pharmacology</i> , <b>2021</b> , 56, 52-60	5.1	6
309	Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofaa588	1	9
308	Beclomethasone dipropionate and sodium cromoglycate protect against airway hyperresponsiveness in a human ex vivo model of cow milk aspiration.. <i>Current Research in Pharmacology and Drug Discovery</i> , <b>2021</b> , 2, 100010	3	1
307	Safety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review. <i>Drug Safety</i> , <b>2021</b> , 44, 273-290	5.1	9

306	Mepolizumab Effectiveness and Allergic Status in Real Life. <i>International Archives of Allergy and Immunology</i> , <b>2021</b> , 182, 311-318	3.7	1
305	Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 611-620	4	4
304	Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies. <i>Expert Review of Respiratory Medicine</i> , <b>2021</b> , 15, 143-152	3.8	15
303	Exploring the Relationship between Disease Awareness and Outcomes in Patients with Chronic Obstructive Pulmonary Disease. <i>Respiration</i> , <b>2021</b> , 100, 291-297	3.7	2
302	Electrocardiographic modifications and cardiac involvement in COVID-19 patients: results from an Italian cohort. <i>Journal of Cardiovascular Medicine</i> , <b>2021</b> , 22, 190-196	1.9	1
301	Drug interaction and chronic obstructive respiratory disorders.. <i>Current Research in Pharmacology and Drug Discovery</i> , <b>2021</b> , 2, 100009	3	2
300	Triple therapy in uncontrolled asthma: a network meta-analysis of phase III studies. <i>European Respiratory Journal</i> , <b>2021</b> , 58,	13.6	13
299	Happy hypoxemia, or blunted ventilation?. <i>Respiratory Research</i> , <b>2021</b> , 22, 4	7.3	7
298	Persistence of both reversible airway obstruction and higher blood eosinophils may predict lung function decline in severe asthma. <i>Clinical Respiratory Journal</i> , <b>2021</b> , 15, 237-243	1.7	2
297	Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs. <i>Expert Opinion on Drug Delivery</i> , <b>2021</b> , 18, 891-906	8	4
296	The Impact of Muscarinic Receptor Antagonists on Airway Inflammation: A Systematic Review. <i>International Journal of COPD</i> , <b>2021</b> , 16, 257-279	3	6
295	Treatable Mechanisms in Asthma. <i>Molecular Diagnosis and Therapy</i> , <b>2021</b> , 25, 111-121	4.5	5
294	Inhaled long-acting muscarinic antagonists in asthma - A narrative review. <i>European Journal of Internal Medicine</i> , <b>2021</b> , 85, 14-22	3.9	8
293	Can placebo challenge test (inducing a "nocebo effect") be a suitable model to assess stress-induced bronchial obstruction? Suggestions from the multidisciplinary Working Groups "Stress-Asthma" and "AAIITO Regione Campania". <i>European Annals of Allergy and Clinical Immunology</i> , <b>2021</b> , 53, 204-207	1.3	
292	Current long-acting muscarinic antagonists for the treatment of asthma. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 2343-2357	4	0
291	Oral Corticosteroids Dependence and Biologic Drugs in Severe Asthma: Myths or Facts? A Systematic Review of Real-World Evidence. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
290	Face masks during COVID-19 pandemic lockdown and self-reported seasonal allergic rhinitis symptoms. <i>Rhinology</i> , <b>2021</b> , 59, 481-484	7	1
289	Use of Thiols in the Treatment of COVID-19: Current Evidence. <i>Lung</i> , <b>2021</b> , 199, 335-343	2.9	2

288	Ceiling effect of beclomethasone/formoterol/glycopyrronium triple fixed-dose combination in COPD: A translational bench-to-bedside study. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2021</b> , 69, 102050	3.5	2
287	An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease. <i>Biologics: Targets and Therapy</i> , <b>2021</b> , 15, 363-374	4.4	2
286	Which LABA/LAMA should be chosen in COPD patients in real life?. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2021</b> , 71, 102076	3.5	0
285	Incidence of pneumomediastinum in COVID-19: A single-center comparison between 1st and 2nd wave. <i>Respiratory Investigation</i> , <b>2021</b> , 59, 661-665	3.4	4
284	Multi-walled carbon nanotubes induce airway hyperresponsiveness in human bronchi by stimulating sensory C-fibers and increasing the release of neuronal acetylcholine. <i>Expert Review of Respiratory Medicine</i> , <b>2021</b> , 15, 1473-1481	3.8	1
283	The Impact of Monoclonal Antibodies on Airway Smooth Muscle Contractility in Asthma: A Systematic Review. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	2
282	Indacaterol, glycopyrronium, and mometasone: Pharmacological interaction and anti-inflammatory profile in hyperresponsive airways. <i>Pharmacological Research</i> , <b>2021</b> , 172, 105801	10.2	3
281	Controversy surrounding the Sputnik V vaccine. <i>Respiratory Medicine</i> , <b>2021</b> , 187, 106569	4.6	7
280	SMART for the treatment of asthma: A network meta-analysis of real-world evidence. <i>Respiratory Medicine</i> , <b>2021</b> , 188, 106611	4.6	2
279	Blood Eosinophils in Chronic Obstructive Pulmonary Disease: Is There Enough Evidence?. <i>US Respiratory &amp; Pulmonary Diseases</i> , <b>2021</b> , 6, 31	0.1	
278	Validation of the risk stratification score in idiopathic pulmonary fibrosis: study protocol of a prospective, multi-centre, observational, 3-year clinical trial. <i>BMC Pulmonary Medicine</i> , <b>2021</b> , 21, 396	3.5	
277	Use of face masks and allergic nasal symptoms: Why not mention pollen count and air pollution data?. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , <b>2021</b> , 103363	2.8	
276	SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis. <i>European Respiratory Journal</i> , <b>2020</b> , 56,	13.6	21
275	Investigational treatments in phase I and II clinical trials: a systematic review in chronic obstructive pulmonary disease (COPD). <i>Expert Opinion on Investigational Drugs</i> , <b>2020</b> , 29, 723-738	5.9	1
274	Does bronchoscopy help the diagnosis in COVID-19 infection?. <i>European Respiratory Journal</i> , <b>2020</b> , 56,	13.6	18
273	Day and Night Control of COPD and Role of Pharmacotherapy: A Review. <i>International Journal of COPD</i> , <b>2020</b> , 15, 1269-1285	3	5
272	What drives inhaler prescription for asthma patients? Results from a real-life retrospective analysis. <i>Respiratory Medicine</i> , <b>2020</b> , 166, 105937	4.6	3
271	A prevalent exposure to male dog is a risk factor for exclusive allergic sensitization to Can f 5: An Italian multicenter study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2020</b> , 8, 2399-2401	5.4	2

270	Pharmacology and Therapeutics of Bronchodilators Revisited. <i>Pharmacological Reviews</i> , <b>2020</b> , 72, 218-252.	52.5	49
269	Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study. <i>Risk Management and Healthcare Policy</i> , <b>2020</b> , 13, 43-53	2.8	7
268	Evaluation of fluticasone propionate/salmeterol for the treatment of COPD: a systematic review. <i>Expert Review of Respiratory Medicine</i> , <b>2020</b> , 14, 621-635	3.8	1
267	Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Drug Delivery</i> , <b>2020</b> , 17, 635-646	8	20
266	The role of triple therapy in the management of COPD. <i>Expert Review of Clinical Pharmacology</i> , <b>2020</b> , 13, 865-874	3.8	4
265	TSLP Inhibitors for Asthma: Current Status and Future Prospects. <i>Drugs</i> , <b>2020</b> , 80, 449-458	12.1	26
264	Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2020</b> , 61, 101899	3.5	26
263	Adding a Second Bronchodilator in COPD: A Meta-Analysis on the Risk of Specific Cardiovascular Serious Adverse Events of Tiotropium/Olodaterol Fixed-Dose Combination. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2020</b> , 17, 215-223	2	0
262	As needed therapies in mild to severe asthma: a systematic review and network meta-analysis <b>2020</b>		2
261	Antitrypsin deficiency and chronic respiratory disorders. <i>European Respiratory Review</i> , <b>2020</b> , 29,	9.8	22
260	Triple Combination Inhalers in Chronic Obstructive Pulmonary Disease and Asthma. <i>US Respiratory &amp; Pulmonary Diseases</i> , <b>2020</b> , 5, 18	0.1	2
259	Sleep and wake impairment in patients with SARS-CoV2 infection. <i>Sleep Medicine</i> , <b>2020</b> , 73, 177-178	4.6	
258	Unmet needs and relationship between general practitioners (GPs) and allergists living in Campania region (southern Italy). <i>European Annals of Allergy and Clinical Immunology</i> , <b>2020</b> , 52, 230-234	1.3	0
257	Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease. <i>Journal of Experimental Pharmacology</i> , <b>2020</b> , 12, 559-574	3	6
256	Anxiety/depression and impaired asthma control in adolescents. Is an increased basal cholinergic tone a possible link ?. <i>European Annals of Allergy and Clinical Immunology</i> , <b>2020</b> , 52, 190-192	1.3	
255	Cardiovascular disease in COPD <b>2020</b> , 47-65		
254	Ergonomical Assessment of Three-Dimensional Versus Two-Dimensional Thoracoscopic Lobectomy. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , <b>2020</b> , 32, 1089-1096	1.7	3
253	Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. <i>Brain, Behavior, and Immunity</i> , <b>2020</b> , 88, 11-16	16.6	95

252	Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo. <i>British Journal of Pharmacology</i> , <b>2020</b> , 177, 1150-1163	8.6	24
251	Severe Asthma and Biological Therapy: When, Which, and for Whom. <i>Pulmonary Therapy</i> , <b>2020</b> , 6, 47-66	3	26
250	A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: The LESDA study. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2020</b> , 60, 101883	3.5	1
249	The impact of comorbidities on severe asthma. <i>Current Opinion in Pulmonary Medicine</i> , <b>2020</b> , 26, 47-55	3	15
248	Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent. <i>Drugs</i> , <b>2020</b> , 80, 1799-1809	12.1	8
247	Expression profiles of the SARS-CoV-2 host invasion genes in nasopharyngeal and oropharyngeal swabs of COVID-19 patients. <i>Heliyon</i> , <b>2020</b> , 6, e05143	3.6	8
246	Real-life Mepolizumab effectiveness in severe eosinophilic asthmatics with nasal polyposis. <i>Respiratory Medicine and Research</i> , <b>2020</b> , 78, 100791	1.4	1
245	Use of mucolytics in COPD: A Delphi consensus study. <i>Respiratory Medicine</i> , <b>2020</b> , 175, 106190	4.6	2
244	The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	2
243	Dyspnea perception and neurological symptoms in non-severe COVID-19 patients. <i>Neurological Sciences</i> , <b>2020</b> , 41, 2671-2674	3.5	4
242	Pharmacological management of adult patients with acute respiratory distress syndrome. <i>Expert Opinion on Pharmacotherapy</i> , <b>2020</b> , 21, 2169-2183	4	3
241	Are there pulmonary sequelae in patients recovering from COVID-19?. <i>Respiratory Research</i> , <b>2020</b> , 21, 286	7.3	29
240	COVID-19 and Genetic Variants of Protein Involved in the SARS-CoV-2 Entry into the Host Cells. <i>Genes</i> , <b>2020</b> , 11,	4.2	48
239	Optimizing de-escalation of inhaled corticosteroids in COPD: a systematic review of real-world findings. <i>Expert Review of Clinical Pharmacology</i> , <b>2020</b> , 13, 977-990	3.8	5
238	Experimental Glucocorticoid Receptor Agonists for the Treatment of Asthma: A Systematic Review. <i>Journal of Experimental Pharmacology</i> , <b>2020</b> , 12, 233-254	3	8
237	Targeting IL-5 pathway against airway hyperresponsiveness: A comparison between benralizumab and mepolizumab. <i>British Journal of Pharmacology</i> , <b>2020</b> , 177, 4750-4765	8.6	8
236	Analysis of ACE2 genetic variants in 131 Italian SARS-CoV-2-positive patients. <i>Human Genomics</i> , <b>2020</b> , 14, 29	6.8	27
235	Pharmacogenomic Response of Inhaled Corticosteroids for the Treatment of Asthma: Considerations for Therapy. <i>Pharmacogenomics and Personalized Medicine</i> , <b>2020</b> , 13, 261-271	2.1	2

234	Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review. <i>Respiratory Medicine</i> , <b>2020</b> , 171, 106114	4.6	14
233	Advances with glucocorticoids in the treatment of asthma: state of the art. <i>Expert Opinion on Pharmacotherapy</i> , <b>2020</b> , 21, 2305-2316	4	9
232	HLA allele frequencies and susceptibility to COVID-19 in a group of 99 Italian patients. <i>Hla</i> , <b>2020</b> , 96, 610-614	1.9	76
231	Highlights of high-resolution computed tomography imaging in evaluation of complications and co-morbidities in idiopathic pulmonary fibrosis. <i>Acta Radiologica</i> , <b>2020</b> , 61, 204-218	2	
230	Anxiety and depression in adolescents with asthma and in their parents. Is an increased basal cholinergic tone a possible further reason to explain the negative impact on asthma control?. <i>Monaldi Archives for Chest Disease</i> , <b>2020</b> , 90,	2.7	2
229	Seasonal monitoring of serum IgE and blood eosinophil variability may lead to a better severe asthma phenotyping and to a correct biologic prescription. <i>Journal of Biological Regulators and Homeostatic Agents</i> , <b>2020</b> , 34, 315-318	0.7	
228	Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients. <i>Advances in Therapy</i> , <b>2019</b> , 36, 3291-3298	4.1	6
227	Ultra-LABAs for the treatment of asthma. <i>Respiratory Medicine</i> , <b>2019</b> , 156, 47-52	4.6	6
226	Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , <b>2019</b> , 156, 78-84	4.6	14
225	A potential role of triple therapy for asthma patients. <i>Expert Review of Respiratory Medicine</i> , <b>2019</b> , 13, 1079-1085	3.8	13
224	Enfentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. <i>Expert Opinion on Investigational Drugs</i> , <b>2019</b> , 28, 827-833	5.9	18
223	Clinical and Functional Characteristics of COPD Patients Across GOLD Classifications: Results of a Multicenter Observational Study. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2019</b> , 16, 215-226	2	11
222	The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone. <i>Clinical Respiratory Journal</i> , <b>2019</b> , 13, 166-173	1.7	4
221	Monoclonal antibodies in severe asthma: is it worth it?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2019</b> , 15, 517-520	5.5	5
220	Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. <i>Respiratory Medicine</i> , <b>2019</b> , 154, 86-92	4.6	13
219	Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics. <i>Trends in Pharmacological Sciences</i> , <b>2019</b> , 40, 452-463	13.2	22
218	Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdoesteine, carbocysteine, and N-acetylcysteine. <i>Respiratory Research</i> , <b>2019</b> , 20, 104	7.3	30
217	Healthcare costs of the SATisfaction and adherence to COPD treatment (SAT) study follow-up. <i>Respiratory Medicine</i> , <b>2019</b> , 153, 68-75	4.6	3



216	Response. <i>Chest</i> , <b>2019</b> , 155, 1079-1080	5.3	1
215	Monoclonal antibodies for severe asthma: Pharmacokinetic profiles. <i>Respiratory Medicine</i> , <b>2019</b> , 153, 3-13	4.6	19
214	Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2019</b> , 56, 39-50	3.5	10
213	Bronchodilators in subjects with asthma-related comorbidities. <i>Respiratory Medicine</i> , <b>2019</b> , 151, 43-48	4.6	7
212	Adding a LAMA to ICS/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD. <i>Chest</i> , <b>2019</b> , 155, 758-770	5.3	56
211	Can f 5 as a suitable marker of dog allergy: Assess male dog exposure before banning it. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 143, 1657-1658	11.5	5
210	Sensitization to Cat: Why Not Use Molecular Diagnostics instead of the Nasal Challenge in Clinical Practice?. <i>International Archives of Allergy and Immunology</i> , <b>2019</b> , 180, 142-143	3.7	
209	Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis. <i>Multidisciplinary Respiratory Medicine</i> , <b>2019</b> , 14, 25	3	6
208	Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2019</b> , 58, 101828	3.5	8
207	CD71 Alveolar Macrophages in Idiopathic Pulmonary Fibrosis: A Look beyond the Borders of the Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 200, 1444-1446	10.2	
206	Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers. <i>Molecular Diagnosis and Therapy</i> , <b>2019</b> , 23, 603-614	4.5	8
205	Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2019</b> , 7, 1643-1646	5.4	6
204	Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2019</b> , 59, 101855	3.5	6
203	Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2019</b> , 59, 101841	3.5	20
202	Diagnostic Performance and Safety of Bronchoalveolar Lavage in Thrombocytopenic Haematological Patients for Invasive Fungal Infections Diagnosis: A Monocentric, Retrospective Experience. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , <b>2019</b> , 11, e2019065	3.2	4
201	Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting βAgonists in COPD: Accumulating Evidence from Network Meta-Analyses. <i>Pulmonary Therapy</i> , <b>2019</b> , 5, 117-126	3	6
200	Pharmacological treatment and current controversies in COPD. <i>F1000Research</i> , <b>2019</b> , 8,	3.6	19
199	Allergy in adolescent population (14-18 years) living in Campania region (Southern Italy). A multicenter study. <i>European Annals of Allergy and Clinical Immunology</i> , <b>2019</b> , 51,	1.3	2

198	The possible concomitant use of aeroallergen and food panels for skin prick testing might enhance the risk of generalized allergic reactions in children. <i>Turkish Journal of Pediatrics</i> , <b>2019</b> , 61, 815-816	0.7	1
197	Systemic pharmacotherapy <b>2019</b> , 215-222		
196	Critical interpretation of pairwise and network meta-analysis of randomized respiratory clinical trials. <i>AboutOpen</i> , <b>2019</b> , 6, 55-61	0.3	
195	Why Are Allergens Not Detected in the Bronchoalveolar Lavage Fluid of Patients Undergoing Fiberoptic Bronchoscopy? Possible Explanations. <i>Journal of Investigational Allergology and Clinical Immunology</i> , <b>2019</b> , 29, 472-473	2.3	
194	Age does not affect the efficacy of anti-IL-5/IL-5R in severe asthmatics. <i>World Allergy Organization Journal</i> , <b>2019</b> , 12, 100081	5.2	6
193	Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 737-750	4	12
192	The future of bronchodilation: looking for new classes of bronchodilators. <i>European Respiratory Review</i> , <b>2019</b> , 28,	9.8	14
191	Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observational study. <i>Therapeutic Advances in Respiratory Disease</i> , <b>2019</b> , 13, 1753466619888128	4.9	7
190	Nonintubated surgical biopsy of undetermined interstitial lung disease: a multicentre outcome analysis. <i>Interactive Cardiovascular and Thoracic Surgery</i> , <b>2019</b> , 28, 744-750	1.8	12
189	Disease awareness in patients with COPD: measurement and extent. <i>International Journal of COPD</i> , <b>2019</b> , 14, 1-11	3	5
188	Effect of lipopolysaccharide on the responsiveness of equine bronchial tissue. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2018</b> , 49, 88-94	3.5	6
187	A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD. <i>Expert Opinion on Drug Safety</i> , <b>2018</b> , 17, 509-517	4.1	4
186	Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab. <i>Expert Opinion on Drug Safety</i> , <b>2018</b> , 17, 429-435	4.1	10
185	Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2018</b> , 50, 28-37	3.5	8
184	Is ICS-LAMA an alternative option to treat patients with COPD?. <i>Lancet Respiratory Medicine</i> , <b>2018</b> , 6, 316-317	35.1	6
183	Clinical effect of corticosteroids in asthma-affected horses: A quantitative synthesis. <i>Equine Veterinary Journal</i> , <b>2018</b> , 50, 594-601	2.4	9
182	Critical aspects in dog allergen immunotherapy (DAI). May Component Resolved Diagnosis (CRD) play a role in predicting the efficacy?. <i>Human Vaccines and Immunotherapeutics</i> , <b>2018</b> , 14, 1438-1441	4.4	5
181	Pleiotropic effects of hypoglycemic agents: implications in asthma and COPD. <i>Current Opinion in Pharmacology</i> , <b>2018</b> , 40, 34-38	5.1	16

180	Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2018</b> , 14, 239-245	5.5	8
179	Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2018</b> , 49, 20-26	3.5	2
178	Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways. <i>Respiratory Research</i> , <b>2018</b> , 19, 65	7.3	20
177	The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. <i>Expert Opinion on Drug Safety</i> , <b>2018</b> , 17, 589-596	4.1	8
176	Impact of doxofylline in COPD: A pairwise meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2018</b> , 51, 1-9	3.5	14
175	Combining long-acting bronchodilators with different mechanisms of action: A pharmacological approach to optimize bronchodilation of equine airways. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , <b>2018</b> , 41, 546-554	1.4	7
174	How does race/ethnicity influence pharmacological response to asthma therapies?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2018</b> , 14, 435-446	5.5	13
173	An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations?. <i>Expert Review of Respiratory Medicine</i> , <b>2018</b> , 12, 43-54	3.8	8
172	Tiotropium could provide benefits in the early stage of COPD, but further studies are needed. <i>BMJ Evidence-Based Medicine</i> , <b>2018</b> , 23, 183-184	2.7	1
171	Emerging antibacterial and antiviral drugs for treating respiratory tract infections. <i>Expert Opinion on Emerging Drugs</i> , <b>2018</b> , 23, 185-199	3.7	2
170	Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights. <i>BMC Pulmonary Medicine</i> , <b>2018</b> , 18, 70	3.5	32
169	Senolytic drugs in respiratory medicine: is it an appropriate therapeutic approach?. <i>Expert Opinion on Investigational Drugs</i> , <b>2018</b> , 27, 573-581	5.9	10
168	Psychological Stress, Lung Function and Exacerbation Risk in COPD: Is an Increase of Cholinergic Tone a Possible Link?. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2018</b> , 15, 310-311	2	4
167	N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation. <i>Biomedicine and Pharmacotherapy</i> , <b>2018</b> , 103, 1-8	7.5	11
166	Allergic sensitization to common pets (cats/dogs) according to different possible modalities of exposure: an Italian Multicenter Study. <i>Clinical and Molecular Allergy</i> , <b>2018</b> , 16, 3	3.7	12
165	Associated Pulmonary Hypertension Is an Independent Contributor to Exercise Intolerance in Chronic Fibrosing Interstitial Pneumonias. <i>Respiration</i> , <b>2018</b> , 96, 543-551	3.7	4
164	Anxiety and asthma in inner-city black adolescents: What could be the underestimated, possible connection?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2018</b> , 6, 1093-1094	5.4	
163	Dog allergy: can a prevalent or exclusive sensitization to Can f 5 be considered a lucky or negative event in real life?. <i>European Annals of Allergy and Clinical Immunology</i> , <b>2018</b> , 50, 283-285	1.3	5

162	Multidimensional approach for the proper management of a complex chronic patient with chronic obstructive pulmonary disease. <i>Expert Review of Respiratory Medicine</i> , <b>2018</b> , 12, 103-112	3.8	1
161	Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 185-194	3.5	13
160	Anxiety and asthma in youth. Is a stress-induced increased cholinergic tone the possible link?. <i>Pediatric Pulmonology</i> , <b>2018</b> , 53, 128-129	3.5	1
159	Staged unilateral lung volume reduction surgery: from mini-invasive to minimalist treatment strategies. <i>Journal of Thoracic Disease</i> , <b>2018</b> , 10, S2754-S2762	2.6	3
158	Occupational exposure to furry animals and asthma: The complex interconnection between work and everyday life. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2018</b> , 121, 512-513	3.2	1
157	Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2018</b> , 14, 1101-1111	5.5	7
156	LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. <i>International Journal of COPD</i> , <b>2018</b> , 13, 3115-3130	3	22
155	Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 2043-2053	4	3
154	Triple therapy single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. <i>European Respiratory Journal</i> , <b>2018</b> , 52,	13.6	78
153	Indoor environmental interventions for furry pet allergens: How to decrease the degree of passive transport. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2018</b> , 6, 1808-1809	5.4	
152	LABA/LAMA Fixed Dose Combination in Chronic Obstructive Pulmonary Disease: The Impact on Health-Related Quality of Life. <i>Respiration</i> , <b>2018</b> , 96, 370-381	3.7	1
151	Multi-dimensional Assessment of IPF Across a Wide Range of Disease Severity. <i>Lung</i> , <b>2018</b> , 196, 707-713	2.9	6
150	Role of statins and mevalonate pathway on impaired HDAC2 activity induced by oxidative stress in human airway epithelial cells. <i>European Journal of Pharmacology</i> , <b>2018</b> , 832, 114-119	5.3	9
149	Multifaceted activity of N-acetyl-L-cysteine in chronic obstructive pulmonary disease. <i>Expert Review of Respiratory Medicine</i> , <b>2018</b> , 12, 693-708	3.8	16
148	LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment. <i>European Respiratory Review</i> , <b>2017</b> , 26,	9.8	43
147	Role of muscarinic antagonists in asthma therapy. <i>Expert Review of Respiratory Medicine</i> , <b>2017</b> , 11, 239-253	3.3	20
146	Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation. <i>Respiratory Research</i> , <b>2017</b> , 18, 26	7.3	37
145	Optimizing drug delivery in COPD: The role of inhaler devices. <i>Respiratory Medicine</i> , <b>2017</b> , 124, 6-14	4.6	97

144	Impact of pulmonary vascular volume on mortality in IPF: is it time to reconsider the role of vasculature in disease pathogenesis and progression?. <i>European Respiratory Journal</i> , <b>2017</b> , 49,	13.6	5
143	Pharmacological treatments in asthma-affected horses: A pair-wise and network meta-analysis. <i>Equine Veterinary Journal</i> , <b>2017</b> , 49, 710-717	2.4	26
142	Is H1-antihistamine (desloratadine 5 mg, orodispersible tablet) premedication in NSAID-associated urticaria really safe and practicable in "real life"?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2017</b> , 5, 535	5.4	4
141	The Challenges of Precision Medicine in COPD. <i>Molecular Diagnosis and Therapy</i> , <b>2017</b> , 21, 345-355	4.5	28
140	Can a better patient phenotyping predict the efficacy of tiotropium in asthmatic adolescents?. <i>Expert Opinion on Pharmacotherapy</i> , <b>2017</b> , 18, 833-835	4	4
139	Indacaterol/Glycopyrronium Combination for COPD. <i>Pulmonary Therapy</i> , <b>2017</b> , 3, 45-57	3	2
138	An update on the pharmacotherapeutic management of lower respiratory tract infections. <i>Expert Opinion on Pharmacotherapy</i> , <b>2017</b> , 18, 973-988	4	6
137	Gender-related Responsiveness to the Pharmacological Treatment of COPD: A First Step Towards the Personalized Medicine. <i>EBioMedicine</i> , <b>2017</b> , 19, 14-15	8.8	10
136	Adherence to COPD treatment: Myth and reality. <i>Respiratory Medicine</i> , <b>2017</b> , 129, 117-123	4.6	37
135	Bronchodilator therapy for chronic cough. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2017</b> , 47, 88-92	3.5	8
134	Withdrawal of inhaled corticosteroids in COPD: A meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 148-158	3.5	45
133	Relationship between oxytocin/vasopressin and latex in obstetric surgery: how to recognize (and prevent) allergic reactions and differentiate them from side effects?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2017</b> , 5, 873	5.4	3
132	Asthma management in a specialist setting: Results of an Italian Respiratory Society survey. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2017</b> , 44, 83-87	3.5	8
131	Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases. <i>Drugs</i> , <b>2017</b> , 77, 721-732	12.1	20
130	Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease. <i>Journal of Comparative Effectiveness Research</i> , <b>2017</b> , 6, 627-636	2.1	3
129	Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi. <i>European Journal of Pharmacology</i> , <b>2017</b> , 812, 147-154	5.3	17
128	Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2017</b> , 14, 526-532	2	16
127	Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2017</b> , 14, 552-563	2	61

126	Anaphylaxis and intimate behaviour. <i>Current Opinion in Allergy and Clinical Immunology</i> , <b>2017</b> , 17, 350-355	3	8
125	Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus. <i>Trends in Pharmacological Sciences</i> , <b>2017</b> , 38, 940-951	13.2	30
124	In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV than long-acting beta-agonists plus inhaled corticosteroids. <i>Evidence-Based Medicine</i> , <b>2017</b> , 22, 183-184		3
123	Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2017</b> , 14, 641-647	2	8
122	Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis. <i>Respiratory Medicine</i> , <b>2017</b> , 129, 189-198	4.6	38
121	Tiotropium formulations and safety: a network meta-analysis. <i>Therapeutic Advances in Drug Safety</i> , <b>2017</b> , 8, 17-30	3.5	20
120	Is the risk of developing atopic sensitization and bronchial asthma in animal laboratory workers preventable in well-defined susceptible individuals?. <i>Journal of Occupational Health</i> , <b>2017</b> , 59, 310-311	2.3	
119	Acute exacerbations of COPD: risk factors for failure and relapse. <i>International Journal of COPD</i> , <b>2017</b> , 12, 2687-2693	3	25
118	What Could the Role of Can f 5 Allergen Be in Dog-Sensitized Patients in "Real Life"?. <i>Journal of Investigational Allergology and Clinical Immunology</i> , <b>2017</b> , 27, 397-398	2.3	3
117	The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. <i>International Journal of COPD</i> , <b>2017</b> , 12, 3469-3485	3	27
116	Benralizumab for the treatment of asthma. <i>Drugs of Today</i> , <b>2017</b> , 53, 633-645	2.5	6
115	Letter to the Editor: Can dog allergen immunotherapy reduce concomitant allergic sensitization to other furry animals? A preliminary experience. <i>European Annals of Allergy and Clinical Immunology</i> , <b>2017</b> , 49, 92-96	1.3	1
114	Clinical features and outcome of hospitalized patients with HSV-1 DNA in the lower respiratory tract. <i>New Microbiologica</i> , <b>2017</b> , 40, 107-112	1.1	1
113	Serum- and Glucocorticoid-Inducible Kinase 1 Delay the Onset of Endothelial Senescence by Directly Interacting with Human Telomerase Reverse Transcriptase. <i>Rejuvenation Research</i> , <b>2016</b> , 19, 79-89	2.6	3
112	Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2016</b> , 4, 791-3	5.4	6
111	The role of epsilon PKC in acute and chronic diseases: Possible pharmacological implications of its modulators. <i>Pharmacological Research</i> , <b>2016</b> , 111, 659-667	10.2	7
110	Glucagon-Like Peptide 1 Receptor: A Novel Pharmacological Target for Treating Human Bronchial Hyperresponsiveness. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2016</b> , 55, 804-814	5.7	28
109	Brain natriuretic peptide: Much more than a biomarker. <i>International Journal of Cardiology</i> , <b>2016</b> , 221, 1031-8	3.2	42

108	Onset of action of budesonide/formoterol Spiromax(®) compared with budesonide/formoterol Turbuhaler(®) in patients with COPD. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2016</b> , 39, 48-53	3.5	6
107	Gastroesophageal reflux and COPD exacerbations: Is cholinergic-mediated oesophago-bronchial reflex a possible link?. <i>Respirology</i> , <b>2016</b> , 21, 1496-1497	3.6	0
106	Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis. <i>Expert Opinion on Drug Safety</i> , <b>2016</b> , 15, 1133-46	4.1	39
105	Do we really need asthma-chronic obstructive pulmonary disease overlap syndrome?. <i>Journal of Allergy and Clinical Immunology</i> , <b>2016</b> , 138, 977-983	11.5	47
104	Dog allergen immunotherapy and allergy to furry animals. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2016</b> , 116, 590	3.2	2
103	Can bronchial asthma with an highly prevalent airway (and systemic) vagal tone be considered an independent asthma phenotype? Possible role of anticholinergics. <i>Respiratory Medicine</i> , <b>2016</b> , 117, 150-3	4.6	20
102	Interaction between corticosteroids and muscarinic antagonists in human airways. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2016</b> , 36, 1-9	3.5	35
101	Treatment options for moderate-to-very severe chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2016</b> , 17, 977-88	4	8
100	How many systemic reactions to skin prick tests could be preventable in defined conditions?. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2016</b> , 116, 174	3.2	3
99	Occupational allergy to horse allergens: More than exposure to horses!. <i>International Journal of Occupational Medicine and Environmental Health</i> , <b>2016</b> , 29, 721-3	1.5	
98	Is Allergic Sensitization to Siberian Hamster Preventable in High-Risk Individuals Who Are Already Sensitized or Exposed to Furry Animals?. <i>Journal of Investigational Allergology and Clinical Immunology</i> , <b>2016</b> , 26, 403-405	2.3	
97	Minimalist video-assisted thoracic surgery biopsy of mediastinal tumors. <i>Journal of Thoracic Disease</i> , <b>2016</b> , 8, 3704-3710	2.6	6
96	The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils. <i>BioMed Research International</i> , <b>2016</b> , 2016, 4547953	3	8
95	Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. <i>Respiratory Research</i> , <b>2016</b> , 17, 70	7.3	58
94	Airflow obstruction: is it asthma or is it COPD?. <i>International Journal of COPD</i> , <b>2016</b> , 11, 3007-3013	3	33
93	The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. <i>Respiratory Medicine</i> , <b>2016</b> , 117, 190-7	4.6	95
92	LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients. <i>Evidence-Based Medicine</i> , <b>2016</b> , 21, 222		9
91	Dysfunction of small airways and prevalence, airway responsiveness and inflammation in asthma: much more than small particle size of pet animal allergens. <i>Upsala Journal of Medical Sciences</i> , <b>2016</b> , 121, 196-7	2.8	1

90	Can pet keeping be considered the only criterion of exposure to cat/dog allergens in the first year of life?. <i>Allergologia Et Immunopathologia</i> , <b>2016</b> , 44, 387-8	1.9	5
89	An unusual outbreak of nontuberculous mycobacteria in hospital respiratory wards: Association with nontuberculous mycobacterial colonization of hospital water supply network. <i>International Journal of Mycobacteriology</i> , <b>2016</b> , 5, 244-7	0.9	11
88	Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update. <i>Drug Safety</i> , <b>2016</b> , 39, 501-8	5.1	26
87	A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. <i>Chest</i> , <b>2016</b> , 149, 1181-96	5.3	160
86	Chronic cat allergen exposure and low sensitization: Possible limitations in patient selection?. <i>Journal of Allergy and Clinical Immunology</i> , <b>2016</b> , 137, 1621-2	11.5	5
85	The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Drug Discovery</i> , <b>2016</b> , 11, 733-44	6.2	26
84	Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2016</b> , 40, 95-103	3.5	80
83	Assessment of pet exposure by questionnaires in epidemiological studies (but also in clinical practice!): Why the questions should be simplified?. <i>Journal of Asthma</i> , <b>2016</b> , 53, 879-81	1.9	4
82	Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease. <i>Drugs</i> , <b>2016</b> , 76, 1257-1270	12.1	26
81	Can the presence of cat/dog at home be considered the only criterion of exposure to cat/dog allergens? A likely underestimated bias in clinical practice and in large epidemiological studies. <i>European Annals of Allergy and Clinical Immunology</i> , <b>2016</b> , 48, 61-4	1.3	9
80	Influence of ethnicity on response to asthma drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2015</b> , 11, 1089-97	5.5	12
79	Cardiovascular disease in patients with COPD. <i>Lancet Respiratory Medicine</i> , <b>2015</b> , 3, 593-5	35.1	16
78	Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients. <i>Respiratory Medicine</i> , <b>2015</b> , 109, 1019-25	4.6	16
77	QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2015</b> , 16, 1079-90	4	13
76	Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives. <i>Drugs</i> , <b>2015</b> , 75, 1575-85	12.1	22
75	Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi. <i>Life Sciences</i> , <b>2015</b> , 131, 44-50	6.8	17
74	Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease. <i>Expert Review of Clinical Pharmacology</i> , <b>2015</b> , 8, 529-39	3.8	10
73	Novel glucocorticoid receptor agonists in the treatment of asthma. <i>Expert Opinion on Investigational Drugs</i> , <b>2015</b> , 24, 1473-82	5.9	14



72	Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. <i>European Respiratory Review</i> , <b>2015</b> , 24, 451-61	9.8	112
71	Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside. <i>Respiratory Medicine</i> , <b>2015</b> , 109, 1305-11	4.6	44
70	Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. <i>European Journal of Pharmacology</i> , <b>2015</b> , 761, 383-90	5.3	28
69	Chronic obstructive pulmonary disease and diabetes. <i>COPD Research and Practice</i> , <b>2015</b> , 1,		18
68	Analysis of exhaled breath fingerprints and volatile organic compounds in COPD. <i>COPD Research and Practice</i> , <b>2015</b> , 1,		22
67	Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2015</b> , 32, 15-23	3.5	37
66	Therapeutic novelties of inhaled corticosteroids and bronchodilators in asthma. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2015</b> , 33, 1-10	3.5	13
65	Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease. <i>Expert Opinion on Drug Safety</i> , <b>2015</b> , 14, 533-41	4.1	29
64	Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease. <i>Expert Review of Clinical Pharmacology</i> , <b>2015</b> , 8, 35-41	3.8	8
63	Indacaterol for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2015</b> , 16, 107-15	4	6
62	Canakinumab for the treatment of chronic obstructive pulmonary disease. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2015</b> , 31, 15-27	3.5	47
61	Translational Study Searching for Synergy between Glycopyrronium and Indacaterol. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2015</b> , 12, 175-81	2	59
60	Fluticasone furoate/vilanterol combination for the treatment of COPD and asthma. <i>Drugs of Today</i> , <b>2015</b> , 51, 469-78	2.5	6
59	Urgent awake thoracoscopic treatment of retained haemothorax associated with respiratory failure. <i>Annals of Translational Medicine</i> , <b>2015</b> , 3, 112	3.2	
58	The complex care of severe emphysema: role of awake lung volume reduction surgery. <i>Annals of Translational Medicine</i> , <b>2015</b> , 3, 108	3.2	7
57	Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold?. <i>Drugs</i> , <b>2014</b> , 74, 1983-92	12.1	23
56	Umeclidinium for the treatment of chronic obstructive pulmonary disease. <i>Expert Review of Respiratory Medicine</i> , <b>2014</b> , 8, 665-71	3.8	14
55	Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2014</b> , 15, 961-77	4	25

54	Diabetes mellitus among outpatients with COPD attending a university hospital. <i>Acta Diabetologica</i> , <b>2014</b> , 51, 933-40	3.9	31
53	Defining phenotypes in COPD: an aid to personalized healthcare. <i>Molecular Diagnosis and Therapy</i> , <b>2014</b> , 18, 381-8	4.5	38
52	The clinical use of regenerative therapy in COPD. <i>International Journal of COPD</i> , <b>2014</b> , 9, 1389-96	3	3
51	Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. <i>European Journal of Pharmacology</i> , <b>2014</b> , 745, 135-43	5.3	71
50	Brain natriuretic peptide protects against hyperresponsiveness of human asthmatic airway smooth muscle via an epithelial cell-dependent mechanism. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2014</b> , 50, 493-501	5.7	17
49	Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond. <i>Expert Opinion on Drug Discovery</i> , <b>2014</b> , 9, 595-607	6.2	7
48	Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD. <i>Respiratory Medicine</i> , <b>2014</b> , 108, 307-13	4.6	5
47	New treatments for COPD in the elderly. <i>Current Pharmaceutical Design</i> , <b>2014</b> , 20, 5968-82	3.3	7
46	Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2013</b> , 346, 414-23	4.7	67
45	Chronic treatment with indacaterol and airway response to salbutamol in stable COPD. <i>Respiratory Medicine</i> , <b>2013</b> , 107, 848-53	4.6	12
44	A 6MWT index to predict O <sub>2</sub> flow correcting exercise induced SpO <sub>2</sub> desaturation in ILD. <i>Respiratory Medicine</i> , <b>2013</b> , 107, 2014-21	4.6	9
43	The effect of indacaterol during an acute exacerbation of COPD. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2013</b> , 26, 630-4	3.5	16
42	The influence of propofol, remifentanyl and lidocaine on the tone of human bronchial smooth muscle. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2013</b> , 26, 325-31	3.5	32
41	Awake thoracoscopic biopsy of interstitial lung disease. <i>Annals of Thoracic Surgery</i> , <b>2013</b> , 95, 445-52	2.7	69
40	Epithelial-smooth muscle cooperation is needed for brain natriuretic peptide-dependent bronchorelaxant activity. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2013</b> , 26, 156-7	3.5	7
39	Asthma and COPD in an Italian adult population: role of BMI considering the smoking habit. <i>Respiratory Medicine</i> , <b>2013</b> , 107, 1417-22	4.6	18
38	β <sub>2</sub> -agonist therapy in lung disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2013</b> , 187, 690-6	10.2	179
37	Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 775-81	4	29

36	Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. <i>Respiratory Medicine</i> , <b>2013</b> , 107, 107-11	4.6	8
35	Comorbidities of asthma: current knowledge and future research needs. <i>Current Opinion in Pulmonary Medicine</i> , <b>2013</b> , 19, 36-41	3	42
34	Inhaled corticosteroids for chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 2489-99	4	23
33	Randomized comparison of awake nonresectional versus nonawake resectional lung volume reduction surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2012</b> , 143, 47-54, 54.e1	1.5	86
32	Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study. <i>Respiratory Medicine</i> , <b>2012</b> , 106, 249-56	4.6	71
31	An update on bronchodilators in Phase I and II clinical trials. <i>Expert Opinion on Investigational Drugs</i> , <b>2012</b> , 21, 1489-501	5.9	28
30	Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. <i>Current Opinion in Pharmacology</i> , <b>2012</b> , 12, 300-8	5.1	15
29	High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2012</b> , 47, 509-16	5.7	51
28	Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. <i>European Respiratory Journal</i> , <b>2012</b> , 40, 101-9	13.6	143
27	Comparative effectiveness of drugs for chronic obstructive pulmonary disease. <i>Drugs of Today</i> , <b>2012</b> , 48, 785-94	2.5	22
26	Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2011</b> , 24, 221-6	3.5	38
25	Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , <b>2011</b> , 20, 291-8		32
24	Asthma and comorbid medical illness. <i>European Respiratory Journal</i> , <b>2011</b> , 38, 42-9	13.6	75
23	Combined pulmonary fibrosis and emphysema: 3D time-resolved MR angiographic evaluation of pulmonary arterial mean transit time and time to peak enhancement. <i>Radiology</i> , <b>2010</b> , 254, 601-8	20.5	33
22	Metabolic syndrome and risk of pulmonary involvement. <i>Respiratory Medicine</i> , <b>2010</b> , 104, 47-51	4.6	15
21	Eosinophilic pneumonia in an asthmatic patient treated with omalizumab therapy: forme-fruste of Churg-Strauss syndrome?. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2009</b> , 64, 1389-90	9.3	10
20	Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2009</b> , 22, 478-82	3.5	25
19	A pilot comparison of helium dilution and plethysmographic lung volumes to assess the impact of a long-acting bronchodilator on lung hyperinflation in COPD. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2009</b> , 22, 522-5	3.5	6

18	Biomarkers of lung damage associated with tobacco smoke in induced sputum. <i>Respiratory Medicine</i> , <b>2009</b> , 103, 1592-613	4.6	37
17	Serum CA 15-3 is increased in pulmonary fibrosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , <b>2009</b> , 26, 54-63	1.1	17
16	Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: a point of view. <i>Respiratory Medicine</i> , <b>2008</b> , 102, 321-7	4.6	24
15	HRCT and histopathological evaluation of fibrosis and tissue destruction in IPF associated with pulmonary emphysema. <i>Respiratory Medicine</i> , <b>2008</b> , 102, 1753-61	4.6	46
14	New perspectives in the treatment of idiopathic pulmonary fibrosis. <i>Therapeutic Advances in Respiratory Disease</i> , <b>2008</b> , 2, 75-93	4.9	21
13	Treating systemic effects of COPD. <i>Trends in Pharmacological Sciences</i> , <b>2007</b> , 28, 544-50	13.2	25
12	Identification of HLA-DRPhebeta47 as the susceptibility marker of hypersensitivity to beryllium in individuals lacking the berylliosis-associated supratypic marker HLA-DPGLubeta69. <i>Respiratory Research</i> , <b>2005</b> , 6, 94	7.3	23
11	Results of unilateral lung volume reduction surgery in patients with distinct heterogeneity of emphysema between lungs. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2005</b> , 129, 73-9	1.5	14
10	Completion lobectomy after bilateral lung volume reduction for emphysema: salvage option or fancy?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2004</b> , 127, 1212-4	1.5	1
9	Feasibility and results of awake thoroscopic resection of solitary pulmonary nodules. <i>Annals of Thoracic Surgery</i> , <b>2004</b> , 78, 1761-8	2.7	189
8	Effect of lung volume reduction surgery for severe emphysema on right ventricular function. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2002</b> , 165, 489-94	10.2	51
7	HLA-DP-unrestricted TNF-alpha release in beryllium-stimulated peripheral blood mononuclear cells. <i>European Respiratory Journal</i> , <b>2002</b> , 20, 1174-8	13.6	20
6	Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2000</b> , 97, 2832-5	11.5	453
5	Thoroscopic reduction pneumoplasty for severe emphysema: do pleural adhesions affect outcome?. <i>Thoracic and Cardiovascular Surgeon</i> , <b>1999</b> , 47, 288-92	1.6	10
4	Endothelial nitric oxide synthase as a potential susceptibility gene in the pathogenesis of emphysema in alpha1-antitrypsin deficiency. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>1999</b> , 20, 441-7	5.7	58
3	Unilateral thoroscopic reduction pneumoplasty for asymmetric emphysema. <i>European Journal of Cardio-thoracic Surgery</i> , <b>1998</b> , 14, 33-9	3	8
2	Immunogenesis of Lung Granulomatosis: New Acquisitions. <i>International Journal of Immunopathology and Pharmacology</i> , <b>1996</b> , 9, 77-77	3	
1	An update on the currently available and emerging synthetic pharmacotherapy for uncontrolled asthma. <i>Expert Opinion on Pharmacotherapy</i> , 1-12	4	1

